Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 4/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9354152 | 1.00 | KCNE1 (0.49) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| SCHEMBL9354158 | 1.00 | KCNE1 (0.49) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| SCHEMBL29653960 | 1.00 | KCNE1 (0.49) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| SCHEMBL29653950 | 1.00 | KCNE1 (0.49) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| SCHEMBL29172252 | 1.00 | KCNE1 (0.49) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11610828 | 0.98 | KCNE1 (0.48) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11610839 | 0.98 | KCNE1 (0.48) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL11610843 | 0.98 | KCNE1 (0.48) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| SCHEMBL21408674 | 0.81 | KCNE1 (0.51) | KCNE1KCNQ1ABCB1MAOAMAOB | |
| SCHEMBL3409162 | 0.80 | KCNE1 (0.38) | KCNE1KCNQ1ABCB1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010027248-A1 | Novel receptor | SMITHKLINE BEECHAM P.L.C. | 2001-10-04 | — | — | US | disclosed |
| US-6245893-B1 | ANTICONVULSANTS, USE IN TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| US-5985334-A | Screening methods to identify anti-convulsant compounds | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-16 | — | — | US | disclosed |
| US-5908860-A | Bicyclic compounds with pharmaceutical activity | SMITHKLINE BEECHAM PLC, (GB) | 1999-06-01 | — | — | US | disclosed |
| EP-0807122-A1 | NOVEL RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996018650-A1 | NOVEL RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-06-20 | — | — | WO | disclosed |
| EP-0673373-A1 | BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | disclosed |
| EP-0126367-B1 | Chroman and chromene derivatives | BEECHAM GROUP PLC (GB) | 1994-10-12 | — | — | EP | disclosed |
| WO-1994013656-A1 | BICYCLIC COMPOUNDS WITH PHARMACEUTICAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | disclosed |
| EP-0095316-B1 | PHARMACEUTICALLY ACTIVE AMINOBENZOPYRANS | BEECHAM GROUP PLC (GB) | 1986-12-03 | — | — | EP | disclosed |
| US-4575511-A | Anti-hypertensive chromanol derivatives | BEECHAM GROUP P.L.C. (GB) | 1986-03-11 | — | — | US | disclosed |
| US-4568692-A | LOWERING BLOOD PRESSURE | BEECHAM GROUP P.L.C. | 1986-02-04 | — | — | US | disclosed |
| EP-0126367-A1 | Chroman and chromene derivatives | BEECHAM GROUP PLC (GB) | 1984-11-28 | — | — | EP | disclosed |
| US-4481214-A | 4-Acylaminobenzopyrans useful as anti-hypertensive agents | BEECHAM GROUP P.L.C. (GB) | 1984-11-06 | — | — | US | disclosed |
| EP-0095316-A1 | Pharmaceutically active aminobenzopyrans | BEECHAM GROUP PLC (GB) | 1983-11-30 | — | — | EP | disclosed |
| US-4110347-A | ANTIHYPERTENSIVE | BEECHAM GROUP LIMITED (GB) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027248-A1 | Novel receptor | ADGRF1, TACR2, GPR4 | KCNE1 919/4885KCNQ1 2260/4885ABCB1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.